Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EKB-569 · 2 trials · 6 indications
| Name | Type | Description |
|---|---|---|
| EKB-569 | DRUG | - |
Inclusion Criteria: * Signed and dated, institutional review board (IRB) or independent ethics committee (IEC)-approved informed consent form before any protocol-specific screening procedures * Histologic and/or cytologic diagnosis of locally-advanced or metastatic non-small cell lung cancer in sub...
EKB-569 is an investigational small molecule being studied for the treatment of colorectal neoplasms and non-small-cell lung carcinoma. It has been evaluated in Phase 2 clinical trials for these advanced solid tumor indications, though it remains in clinical development and is not approved.
EKB-569 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer has sponsored clinical trials evaluating the drug in patients with advanced non-small-cell lung cancer and advanced colorectal cancer.
EKB-569 is in Phase 2 clinical development. Two Phase 2 studies have been completed, one in advanced non-small-cell lung cancer and one in advanced colorectal cancer. The drug is investigational and has not been approved by regulatory authorities.
EKB-569 has been studied in two completed Phase 2 trials. NCT00067548 evaluated the drug in 44 patients with advanced non-small-cell lung cancer, and NCT00072748 evaluated it in 63 patients with advanced colorectal cancer. Both trials enrolled adults aged 18 years and older.
EKB-569 is a distinct investigational compound developed by Pfizer. It is not known by any other names in the available clinical trial data. The drug is a small molecule being studied for its potential effects in certain types of cancer.